[e-drug] Workshop on pharmacogenetics of drug metabolism

[Collen Masimirembwa <Collen.Masimirembwa@astrazeneca.com>]

E-drug: Workshop on pharmacogenetics of drug metabolism
-------------------------------------------------------------------------

Dear Colleagues

Can you please also pass the information about this 3-day
workshop on Pharmacogenetics of Drug Metabolism to your
graduate students who might not have access to the internet.

thank you.

Collen Masimirembwa (PhD, DPhil)
Associate Principal Scientist
Dept DMPK & Bioanalytical Chemistry
AstraZeneca Molndal
S-431 83 Molndal
Sweden
Tel: 46 31 776 2201
Fax: 46 31 776 37 86
collen.masimirembwa@astrazeneca.com


3-Day Workshop on Pharmacogenetics of Drug Metabolism

Organisation: African Institute of Biomedical Science and
Technology (AiBST)
Website: www.aibst.com
Event: 3-D Workshop on Pharmacogenetics of Drug Metabolism
When: 25-27th of August, 2003
Place: Nairobi, Kenya
Contact person: Dr. Collen Masimirembwa
(collen.masimirembwa@aibst.com)
Registration forms and scholarship application forms: 
www.aibst.com to contact Dr. Collen Masimirembwa (above
e-mail).
Stortfjallsgatan 10, 431 35 Molndal, Sweden.
Fax: +46 31 27 92 73


Pharmacogenetics of Drug Metabolism

3-DAY WORKSHOP

Nairobi, Kenya
PanAfric Hotel
25-27 August 2003

Number of participants: 30

Workshop
At the end of the course the students must be familiar with the
major polymorphisms of drug metabolising enzymes with respect to
their genotypes, phenotypes and population distributions. The
students must be able to identify clinical situations where these
polymorphisms might affect treatment outcome. From a methodolo-
gical point of view, they must become aware of the many probes
used in phenotyping and how such data is interpreted. As an
exercise they will analyse urine samples from a phenotyping study
for CYP2D6 and CYP2C19. With respect to genotyping, they will
also become acquainted to the molecular biology technical
advances. For exercise, they will use multiplex PCR to genotype for
the CYP2D6 and PCR-RFLP for CYP2C19 genetic polymorphisms.
At the end of the course most of the participants will be able to go
back to initiate genotyping and phenotyping experiments with
follow-up assistance from AiBST.

Tutors
(1) Professor Leif Bertilsson (Professor, Dept of Clinical
Pharmacology, Huddinge University Hospital, Karolinska Institute,
Sweden)
(2) Professor Olavi Pelkonen (Professor, Dept of Pharmacology and
Toxicology. Univ. Oulu, Finland)
(3) Prof. Gilbert Kokwaro (Professor of Clinical Pharmacology,
Kenya)
(4) Dr. Andrea Gaigek (Associate Director, The Children's Mercy
Hospital, Dept of Clin. Pharmacology, USA)
(5) Dr. Collet Dandara (Research Scientist, Univ. Zimbabwe and
AiBST Labs. Zimbabwe)
(6) Dr. Collen Masimirembwa (Associate Principal Scientist, DMPK
and BAC, AstraZeneca R&D, M=F6lndal, Sweden)

Monday

(1) Overview of the drug discovery process and Pharmacogenetics
in the Pharma Business 

(2) The history and origin of pharmacogenetics of drug metabolising
enzymes

(3) Basic Genetics and Molecular Biology terminologies &
technologies 

(4) The molecular, kinetic, phenotypic discovery and
characterisation of GST, NAT-2, EH, UGTs polymorphisms 

(5) The molecular, kinetic, phenotypic discovery and
characterisation of CYP450, and FMO polymorphisms 

Practical work in the afternoon:
(a) Urines from subjects who will have been phenotyped using a
combination of Debrisoquine and Mephenytoin will be available.
Students will carry out extractions and HPLC analysis. 

Tuesday

(6) Clinical implications of genetic polymorphism of drug
metabolism...individualised treatment and cost benefit analysis. 

(7) Xenobiotic-metabolising enzymes and cancer risk:
correspondance between genotype and phenotype 

(8) HTS genotyping methods for Clinical Pharmacogenetics 

(9) Pharmacogenetic status of drug metabolising enzymes in African
populations....molecular and phenotypic basis 

(10) The metabolism and pharmacokinetics of anti-infectives:
implications for chemotherapy and drug resistance and potential
role of polymorphisms of drug metabolising enzymes (PK/PD-Tox) 

(11) Practical Experiences of Clinical Studies invovling
Pharmacogenetic issues 

Practical work in the afternoon
(a) DNA samples from a number of subjects, including those with
the urines analysed on Monday will be available. Students will carry
out multiplex PCR for CYP2D6 and PCR-RFLP for CYP2C19 genetic
variants.

Wednesday

(12) Evaluation of Phenotyping methods for drug metabolising
enzymes and design of clinical studies to evaluate impact on drug
use 

(13) Data evaluation of population pharmacogenetic data
(phenotype and genotype) 

(14) The design and excution of epidemiological and clinical studies
to evaluate disease susceptibility and adverse effects profiles 

(15) Enzyme Kinetic and Molecular Modelling of
enzyme-substrate/inhibitor interactions for polymorphic enzymes,
CYP2C9 and CYP2D6. 

(16) Ethics and Legal Issues in Pharmacogenetics research 

Practical work in the afternoon
Evaluation and interpretation of results of phenotyping and
genotyping studies.

Leif, Andrea and Collen.

--
To send a message to E-Drug, write to: e-drug@usa.healthnet.org
To subscribe or unsubscribe, write to: majordomo@usa.healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@usa.healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug